The guanylate-binding protein 5 (GBP5) is a member of the interferon (IFN)-inducible GTPase family, which plays critical roles in innate immunity and inflammatory responses. GBP5 is primarily expressed in immune cells, such as macrophages and endothelial cells, and its expression is strongly upregulated by proinflammatory cytokines (e.g., IFN-γ) or pathogen-associated molecular patterns (PAMPs). Structurally, GBP5 contains a conserved N-terminal GTPase domain and a C-terminal helical domain, enabling its oligomerization and participation in host defense mechanisms.
Functionally, GBP5 is implicated in regulating inflammasome activation, antimicrobial defense, and cytokine secretion. Studies suggest it restricts intracellular pathogens (e.g., bacteria, viruses) by disrupting pathogen membranes or modulating immune signaling pathways. For example, GBP5 interacts with components of the NLRP3 inflammasome to enhance caspase-1 activation, promoting IL-1β processing. It also restricts HIV-1 infection by interfering with viral capsid assembly.
GBP5 antibodies are essential tools for investigating its expression, localization, and mechanistic roles in immune regulation. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study GBP5’s involvement in diseases such as sepsis, autoimmune disorders, and infections. Dysregulation of GBP5 has been linked to chronic inflammation and cancer, highlighting its therapeutic and diagnostic potential. Research on GBP5 continues to uncover its dual roles in pathogen defense and immune homeostasis.